Publications by authors named "Elena Ribakovsy"
Article Synopsis
- A phase II clinical study evaluated the effectiveness of a treatment combo (ibrutinib, bendamustine, and rituximab) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after stem cell transplants or in elderly patients.
- The study showed a 49.1% overall response rate among patients who received at least one cycle, with better outcomes for those with relapsed disease (72.3%) versus refractory disease (37.8%).
- Patients experiencing complete or partial responses had significantly longer median overall survival of 28.1 months, while common side effects included fatigue, diarrhea, and nausea, indicating that the treatment is both safe and effective for those needing potential transplantation.
Background: Brentuximab-vedotin (BV) monotherapy has shown high efficacy in heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma (HL) after high-dose chemotherapy or autologous stem cell transplantation (ASCT). We retrospectively analyzed the outcomes of treatment with BV of HL patients and examined the predictive ability of PET-CT for response in this setting.
Patients And Methods: Records of 49 HL patients (median age, 39 years, 55% male) treated with BV for relapse (71.
The choice of a rituximab-based regimen and the prognostic significance of interim 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in primary mediastinal large B cell lymphoma (PMBCL) are debatable. We evaluated the clinical features and outcomes of 95 consecutive patients with PMBCL who were treated between 1985 and 2009. Forty-three patients received rituximab-based chemotherapy, R-VACOP-B (N = 30) or R-CHOP21 (N = 13), whereas 52 patients were treated with VACOP-B (N = 47) or CHOP21 (N = 5).
View Article and Find Full Text PDF